Table 2.

Study outcomes in the control group compared to the active group.

	Control Group (n = 25)	Active Group (n = 25)	p-Value
4-month period (active phase)
Episodes of respiratory infections (n)	2 (1–3)	1 (0–2)	0.02
Duration of symptoms (days)	6 (5–9)	3 (0–6)	0.01
Absence from school (days)	6 (2–8)	3 (0–7)	0.15
2-month period (follow-up)
Episodes of respiratory infections (n)	0 (0–1)	1 (0–1)	0.23
Duration of symptoms (days)	0 (0–4)	0 (0–3)	0.84
Absence from school (days)	0 (0–4)	0 (0–0)	0.60
Total period
Treated with antibiotics, n (%)	9 (36)	12 (48)	0.39
Treated with cortisone, n (%)	15 (60)	8 (32)	0.047
Patients with fever, n (%)	16 (64)	12 (48)	0.25
Patients with COVID, n (%)	2 (8)	1 (4)	1.00
Patients with flu vaccine, n (%)	9 (36)	9 (36)	1.00

Data are reported as median and interquartile range, or absolute number and percentage.